A phase I randomized placebo controlled trial of the safety of 3% SPL7013 gel (VivaGel®) in healthy young women administered twice daily for 14 days

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Cohen, Craig R ^a   Brown, Joelle ^b   Moscicki, Anna Barbara ^a   Bukusi, Elizabeth A ^c   Paull, Jeremy R A ^d   Price, Clare F ^d   Shiboski, Stephen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d Starpharma Holdings Limited   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PLACEBO; VIVAGEL; ANTIINFECTIVE AGENT; POLYLYSINE;

ABRASION; ADULT; ARTICLE; COLPOSCOPY; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HEMATURIA; HUMAN; HUMAN EXPERIMENT; KENYA; LABORATORY TEST; LACERATION; LACTOBACILLUS; METRORRHAGIA; MORNING DOSAGE; MULTICENTER STUDY; MUSCLE CRAMP; NEUROLOGIC DISEASE; NORMAL HUMAN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEXUAL BEHAVIOR; SIDE EFFECT; ULCER; UNITED STATES; URINARY FREQUENCY; UTERINE CERVIX DISEASE; VAGINA DISCHARGE; VAGINA FLORA; VAGINITIS; VULVA DISEASE; ADOLESCENT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOXICITY; ERYTHEMA; GEL; INTRAVAGINAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; UROGENITAL TRACT DISEASE;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; COLPOSCOPY; DRUG TOXICITY; ERYTHEMA; FEMALE; FEMALE UROGENITAL DISEASES; GELS; HUMANS; KENYA; LACTOBACILLUS; POLYLYSINE; SEXUAL ABSTINENCE; UNITED STATES; YOUNG ADULT;

EID: 79251604177     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016258     Document Type: Article

References (26)

1. UNAIDS (2008) Joint United Nations Programme on HIV/AIDS. Report on the global AIDS epidemic.
2. National AIDS and STI Control Programme MoH K (2008) Kenya AIDS Indicator Survey 2007: Preliminary Report.
3. Fleming DT, Wasserheit JN (1999) From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 75: 3-17.
4. Gong E, Matthews B, McCarthy T, Chu J, Holan G, et al. (2005) Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses. Antiviral Res 68: 139-146.
5. Bourne N, Zaneveld LJ, Ward JA, Ireland JP, Stanberry LR (2003) Poly(sodium 4-styrene sulfonate): evaluation of a topical microbicide gel against herpes simplex virus type 2 and Chlamydia trachomatis infections in mice. Clin Microbiol Infect 9: 816-822.
6. Dezzutti C, James V, Ramos A, Sullivan S, Siddig A, et al. (2004) In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob Agents Chemother 48: 3834-3844.
7. Gong Y, Matthews B, Cheung D, Tam T, Gadawski I, et al. (2002) Evidence of dual sites of action of dendrimers: SPL-2999 inhibits both virus entry and late stages of herpes simplex virus replication. Antiviral Res 55: 319-329.
8. Witvrouw M, Fikkert V, Pluymers W, Matthews B, Mardel K, et al. (2000) Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. Mol Pharmacol 58: 1100-1108.
9. Patton DL, Cosgrove Sweeney YT, McCarthy TD, Hillier SL (2006) Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model. Antimicrob Agents Chemother 50: 1696-1700.
10. O'Loughlin J, Millwood IY, McDonald HM, Price CF, Kaldor JM, et al. (2009) Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study. Sex Transm Dis 37: 100-104.
11. Mauck C, Rosenberg Z, Van Damme L (2001) Recommendations for the clinical development of topical microbicides: an update. AIDS 15: 857-868.
12. CONRAD/WHO (2004) Manual for the Standardization of Colposcopy for the Evaluation of Vaginal Products. Update 2004.
13. Nugent R, Krohn M, Hillier S (1991) Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 29: 297-301.
14. Chen M, Macaluso M, Blackwell R, Galvao L, Kulczycki A, et al. (2007) Selfreported mechanical problems during condom use and semen exposure. Comparison of two randomized trials in the United States of America and Brazil. Sex Transm Dis 34: 557-562.
15. Wallace A, Teitelbaum A, Wan L, Mulima M, Guichard L, et al. (2007) Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception 76: 53-56.
16. Melendez J, Giles J, Yuenger J, Smith T, Ghanem K, et al. (2007) Detection and quantification of Y-chromosomal sequences by real-time PCR using the LightCycler system. Sex Transm Dis 34: 617-619.
17. McGowan I, Gomez K, Emmanuel P, Febo I, Chen BA, et al. (2010) A Phase I Study of the Safety and Acceptability of 3% w/w SPL7013 (VivaGel) Applied Vaginally in Sexually Active Young Women (MTN-004). Microbicides 2010. Pittsburgh, PA.
18. Cohen C, Moscicki A, Scott M, Ma Y, Shiboski S, et al. (2010) Increased levels of immune activation in the genital tract of healthy young women from sub- Saharan Africa. AIDS 24: 2069-2074.
19. Ballagh SA, Baker JM, Henry DM, Archer DF (2002) Safety of single daily use for one week of C31G HEC gel in women. Contraception 66: 369-375.
20. Hoffman IF, Taha TE, Padian NS, Kelly CW, Welch JD, et al. (2004) Nonoxynol-9 100 mg gel: multi-site safety study from sub-Saharan Africa. AIDS 18: 2191-2195.
21. Malonza IM, Mirembe F, Nakabiito C, Odusoga LO, Osinupebi OA, et al. (2005) Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel. AIDS 19: 2157-2163.
22. Mauck CK, Weiner DH, Creinin MD, Barnhart KT, Callahan MM, et al. (2004) A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II. Contraception 70: 233-240.
23. Mayer KH, Peipert J, Fleming T, Fullem A, Moench T, et al. (2001) Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin Infect Dis 32: 476-482.
24. Schwartz JL, Mauck C, Lai JJ, Creinin MD, Brache V, et al. (2006) Fourteenday safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception 74: 133-140.
25. van De Wijgert J, Fullem A, Kelly C, Mehendale S, Rugpao S, et al. (2001) Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites. J Acquir Immune Defic Syndr 26: 21-27.
26. van de Wijgert JH, Kilmarx PH, Jones HE, Karon JM, Chaikummao S (2008) Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials. Contraception 77: 122-129.